Charles Sawyers

☆ Save On Wikipedia ↗
Charles L. Sawyers
Born
Charles Lazelle Sawyers[1]

1959 (age 66–67)
Nashville, Tennessee
EducationJohns Hopkins University, Princeton, UCSF
Medical career
ProfessionPhysician
InstitutionsMemorial Sloan Kettering Cancer Center
Howard Hughes Medical Institute
Sub-specialtiesOncologist
ResearchLeukemia/prostate cancer
AwardsLasker Clinical Award (2009)
BBVA Foundation Frontiers of Knowledge Award (2014)
WebsiteThe Charles Sawyers Lab

Charles L. Sawyers (born 1959) is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.[2]

Career

Sawyers received a BA from Princeton University in 1981 and an MD from Johns Hopkins University School of Medicine in 1985,[3] followed by an internal medicine residency at the University of California, San Francisco.[4] He became a HHMI investigator in 2002 while working at UCLA's Jonsson Cancer Center.[5]

Sawyers works on molecularly targeted cancer drugs, with a focus on developing a new generation of treatment options for patients. He shared the 2009 Lasker-DeBakey Clinical Medical Research Award with Brian J. Druker and Nicholas Lydon,[6] for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second-generation ABL inhibitor dasatinib to overcome imatinib resistance. He also co-discovered the antiandrogen drugs enzalutamide, approved by the FDA in 2012, and apalutamide[7] approved in 2019, both for treatment of advanced prostate cancer.[8]

Sawyers' cancer research is discussed in the second episode of Cancer: The Emperor of All Maladies.

Significant positions

Sawyers served as president of the American Society for Clinical Investigation (ASCI) in 2007[9] and of the American Association for Cancer Research (AACR) in 2012.[10] He was also appointed to the National Cancer Advisory Board by President Obama in 2012,[11] and has served on the Board of Directors of Novartis since 2013.[12] He was a founding co-editor of the Annual Review of Cancer Biology in 2017,[13] serving until 2021.[14]

Memberships

Awards

References

  1. Howard Hughes Medical Institute, Annual Scientific Report, The Institute, 1990, p. 507.
  2. "At Work: Human Oncology and Pathogenesis Program Chair Charles Sawyers | Memorial Sloan Kettering Cancer Center". www.mskcc.org. Retrieved April 5, 2017.
  3. "Susan Schneck Weds Charles Sawyers". The New York Times. October 22, 1990. Retrieved March 3, 2017.
  4. "UCSF Department of Medicine Alumni Profile: Dr. Charles Sawyers". medicine.ucsf.edu. Archived from the original on September 8, 2015. Retrieved March 3, 2017.
  5. "Charles L. Sawyers, MD". HHMI.org. Retrieved April 5, 2017.
  6. Grindlinger, Brooke; Chao, ES (October 1, 2009). "Trio receives Lasker Foundation Clinical Award for breakthroughs in leukemia treatment". Journal of Clinical Investigation. 119 (10): 2863–2865. doi:10.1172/JCI41141. ISSN 0021-9738. PMC 2752112.
  7. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009). "Development of a second-generation antiandrogen for treatment of advanced prostate cancer". Science. 324 (5928): 787–90. Bibcode:2009Sci...324..787T. doi:10.1126/science.1168175. PMC 2981508. PMID 19359544.
  8. Reyes, Antonio A.; Akeson, Richard (1988). "Generation of Multiple Independent Substitution Mutants by M13 in Vitro Mutagenesis Using a Single Mutagenic Oligonucleotide". DNA. 7 (8): 579–584. doi:10.1089/dna.1.1988.7.579. PMID 3180999.
  9. "2008 American Society for Clinical Investigation Presidential Address" (PDF). the-asci.org. Retrieved March 3, 2017.
  10. "Charles L. Sawyers, MD". aacr.org. Retrieved March 4, 2017.
  11. "President Obama Announces More Key Administration Posts". whitehouse.gov. December 6, 2012. Retrieved March 4, 2017.
  12. "Charles L. Sawyers, M.D. Member of the Board of Directors" (PDF). novartis.com. Retrieved March 4, 2017.
  13. Jacks, Tyler; Sawyers, Charles (2017). "Introduction". Annual Review of Cancer Biology. 1: i. doi:10.1146/annurev-ca-01-121516-100001.
  14. "Annual Review of Cancer Biology Editorial Committee". Annual Reviews. 2022. Retrieved July 18, 2022.
  15. "Doris Duke Charitable Foundation Awards $10.5 Million for Medical Research". Philanthropy News Digest (PND). Retrieved April 5, 2017.
  16. "Recipients of the David A. Karnofsky Memorial Award and Lecture - The ASCO Post". www.ascopost.com. Archived from the original on September 19, 2017. Retrieved April 5, 2017.
  17. "Awards, Appointments, Announcements". JNCI Journal of the National Cancer Institute. 97 (11): 797. June 1, 2005. doi:10.1093/jnci/97.11.797.
  18. "Dorothy P. Landon-AACR Prize for Translational Cancer Research". www.aacr.org. Archived from the original on September 3, 2017. Retrieved April 5, 2017.
  19. Foundation, Lasker. "Molecularly targeted treatments for chronic myeloid leukemia | The Lasker Foundation". The Lasker Foundation. Retrieved April 5, 2017.
  20. "Breakthrough Prize". breakthroughprize.org. Retrieved April 5, 2017.
  21. "Taubman Prize". A. Alfred Taubman Medical Research Institute. Retrieved March 16, 2017.
  22. "2014 Honorees". The Hope Funds for Cancer Research. September 5, 2013. Retrieved April 5, 2017.
  23. "BBVA Foundation Frontiers of Knowledge Awards". www.fbbva.es. Archived from the original on September 21, 2015. Retrieved April 5, 2017.